Example: marketing
DRUG NAME: Lenvatinib - BC Cancer
baseline and as needed during treatment in patients at risk for QT prolongation (e.g., congenital long QT syndrome, history of cardiac disease, or receiving concurrent therapy with QT/QTc interval-prolonging drugs ). Patients should report any …
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
BC CANCER HAZARDOUS DRUG LIST
www.bccancer.bc.caBC CANCER HAZARDOUS DRUG LIST (Refer to: Pharmacy Directive VI-80 Hazardous Drug List) The BC Cancer Hazardous Drug List (BC Cancer HD List) is comprised of:
Safe Handling of Hazardous Drugs - BC Cancer
www.bccancer.bc.caA.1 Potential Hazards of Handling Hazardous Drugs..... 1 A.2 Hazardous Drug List.....
Oncology Nutrition High Protein High Energy …
www.bccancer.bc.caHigh Protein High Energy Food Choices 3 Examples of High Protein Foods • All meat (eg. beef, pork, goat, lamb) • Fish and shellfish • All poultry (eg. chicken, turkey, duck)
“Magic” mouthwash explained - BC Cancer
www.bccancer.bc.caFAMILY PRACTICE ONCOLOGY NETWORK JOURNAL / FALL 2014 3 “Magic” mouthwash explained By Dr. Allan Hovan, Provincial Professional Practice Leader,
Symptom Management Guidelines: ORAL …
www.bccancer.bc.caSymptom Management Guidelines: ORAL MUCOSITIS . Definition Oral Mucositis (Stomatitis): An acute inflammation and/or ulceration of the …
Guidelines for Management of CID - BC Cancer
www.bccancer.bc.caDisclaimer Both the format and content of the guidelines will change as they are reviewed and revised on a periodic basis. Any physician using these guidelines to provide
British Columbia Cancer Agency POLICY
www.bccancer.bc.caBritish Columbia Cancer Agency ¦ POLICY Title: PREVENTION AND MANAGEMENT OF EXTRAVASATION OF CHEMOTHERAPY Number: III-20 Effective Date: Provincial Systemic Program September 1,1997
Symptom Management Guidelines: FEVER AND …
www.bccancer.bc.caSymptom Management Guidelines: FEVER AND NEUTROPENIA . Definition • Fever: A single oral temperature of ≥ 38.3° C (101° F) OR a temperature ≥ 38 ° C (100.4 ° F) which lasts more than 1h
Symptom Management Guidelines: XEROSTOMIA
www.bccancer.bc.caSymptom Management Guidelines: XEROSTOMIA. Definition(s) • Xerostomia: abnormal dryness in the mouth characterized by a marked decrease and/or thickening of saliva, may be
Linking the BC Psychosocial Community Oncology …
www.bccancer.bc.caCarolyn Jacob - New Regional Professional Practice Leader at the Centre for the North. We welcome Carolyn Jacob, MSW, RSW to her new role at the BC
Related documents
DRUG INDUCED QT PROLONGATION - GGC Medicines
ggcmedicines.org.ukof drug induced QT prolongation and drug interactions. Interactions There are three mechanisms by which drugs can interact and increase the risk of QT prolongation:6 Pharmacodynamic Interaction: The concurrent use of more than one drug that prolongs the QT interval increases the risk of torsades de pointes and ventricular arrhythmia.
Drugs Associated with QT Interval Prolongation
www.cpsbc.caDescribes whether the FDA-approved product labelling includes mention of QT prolongation, torsades de pointes, or both. 2–65. d . Drug reported in the product labelling to prolong the QT interval, but evidence to support such an effect is lacking or published data suggest otherwise. 1.
DRUG NAME: Osimertinib - BC Cancer
www.bccancer.bc.caelectrolyte abnormalities , and/or are receiving concurrent QT interval prolonging medication require monitoring throughout treatment. Interrupt treatment for QTc intervals of 500 ms or greater, and consider resuming at a reduced dose once the QTc interval is less than 481 ms or returns to baseline. If QT interval prolongation is accompanied by
Drug Discovery and Preclinical Development
www.lehigh.eduCompound #1: hERG Test for QT Prolongation Values shown are Inhibition of Current (%) + SEM Test Compound % Inhibition SEM Compound 1 32.9 1.5 Positive Control 76.7 2.8 (tf diterfenadine 60 nM) Conducted by ChanTest, Inc; Covance GLP study 7252-117 Results: IC50 = 1.9 μM indicating low risk of cardiac arrhythmias based